Page 84 - Demo

34. Stadtmauer, E. A., Fraietta, J. A., Davis, M. M.,Cohen, A. D., Weber, K. L., Lancaster, E.,Mangan, P. A., Kulikovskaya, I., Gupta, M.,Chen, F., Tian, L., Gonzalez, V. E., Xu, J.,Jung, I. Y., Melenhorst, J. J., Plesa, G.,Shea, J., Matlawski, T., Cervini, A., Gaymon,A. L., %u2026 June, C. H. CRISPR-engineered Tcells in patients with refractory cancer.Science (New York, N.Y.), 2020, 367(6481),eaba7365.https://doi.org/10.1126/science.aba736528. Wong, T. K., Neumann, E. Electric fieldmediated gene transfer. Biochemical andbiophysical research communications, 1982,107(2), 584%u2013587. https://doi.org/10.1016/0006-291x(82)91531-5 29. Laustsen, A., Bak, R. O. ElectroporationBased CRISPR/Cas9 Gene Editing Using Cas9Protein and Chemically Modified sgRNAs.Methods in molecular biology (Clifton, N.J.),2019, 1961, 127%u2013134.https://doi.org/10.1007/978-1-4939-9170-9_9 30. Wang, Z., Li, N., Feng, K., Chen, M., Zhang, Y.,Liu, Y., Yang, Q., Nie, J., Tang, N., Zhang,X., Cheng, C., Shen, L., He, J., Ye, X., Cao,W., Wang, H., & Han, W. Phase I study ofCAR-T cells with PD-1 and TCR disruption inmesothelin-positive solid tumors. Cellular molecular immunology, 2021, 18(9), 2188%u20132198.https://doi.org/10.1038/s41423-021-00749-x 31. Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang,L., Wei, G., Han, L., Wang, H., Yu, S., Chen,Y., Wang, Y., He, X., Zhang, X., Gao, M.,Yang, J., Li, X., Ren, J., Huang, H.CRISPR/Cas9-Engineered UniversalCD19/CD22 Dual-Targeted CAR-T CellTherapy for Relapsed/Refractory B-cellAcute Lymphoblastic Leukemia. Clinicalcancer research, 2021, 27(10), 2764%u20132772.https://doi.org/10.1158/1078-0432.CCR-20-3863 32. Ottaviano, G., Georgiadis, C., Gkazi, S. A.,Syed, F., Zhan, H., Etuk, A., Preece, R., Chu,J., Kubat, A., Adams, S., Veys, P., Vora, A.,Rao, K., Qasim, W., & TT52 CRISPR-CARgroup Phase 1 clinical trial of CRISPRengineered CAR19 universal T cells fortreatment of children with refractory B cellleukemia. Science translational medicine,2022, 14(668), eabq3010.https://doi.org/10.1126/scitranslmed.abq301033. Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T.,Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng,S., Wang, C. L., Yuen, B., Dalmas, O.,Heeringa, K., Sennino, B., Conroy, A.,Bethune, M. T., Mende, I., White, W.,Kukreja, M., Gunturu, S., %u2026 Mandl, S. J. Nonviral precision T cell receptor replacementfor personalized cell therapy. Nature, 2023,615(7953), 687%u2013696.https://doi.org/10.1038/s41586-022-05531-182ANALESRANFwww.analesranf.comIModulation of the immune system to fight cancer usingCRISPR-Cas9, dependent or independent of CAR-TtechnologySamuel Torrej%u00f3n y Caroline WeinsteinAn. R. Acad. Farm.Vol. 91. n%u00ba1 (2025) %u00b7 pp. 67-82Si desea citar nuestro art%u00edculo:Modulaci%u00f3n del sistema inmune para combatirel c%u00e1ncer mediante CRISPR-Cas9, dependienteo independiente de la tecnolog%u00eda CAR-TSamuel Torrej%u00f3n Gonz%u00e1lez y Caroline Weinstein OppenheimerAn Real Acad Farm (Internet).An. Real Acad. Farm.Vol. 91. n%u00ba 1 (2025) %u00b7 pp.67-82DOI:http://dx.doi.org/10.53519/analesranf.2025.91.01.03